Clinical Trials

44 enrolled

Breast Neoplasms

NCT06671912 2026-03-04

LoTam

Phase 3 Suspended

1,156 enrolled

Breast Carcinoma In Situ

NCT02767661 2026-02-27

MECCA

263 enrolled

Breast Neoplasms

NCT06507618 2026-02-24

POWER II

354 enrolled

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

518 enrolled 15 charts

Breast Neoplasms

NCT01953588 2026-01-22

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

1,473 enrolled

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

1,903 enrolled

Breast Neoplasms

NCT04584853 2026-01-14

POETIC-A

123 enrolled

Breast Cancer Female

NCT03079011 2025-11-18

PADA-1

1,017 enrolled

Breast Neoplasms

NCT07190443 2025-09-29

AURA

290 enrolled

Breast Neoplasms

NCT04158362 2025-09-22

AMBRE

180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04134598 2025-08-29

EUROPA

926 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

474 enrolled

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

NCT00253422 2025-06-04

SoFEA

698 enrolled 19 charts

Breast Neoplasms

NCT00265759 2025-04-23

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

622 enrolled 18 charts

Phase 3 Not yet recruiting

Breast Neoplasms

NCT06223698 2025-04-20

SWE-Switch

3,832 enrolled

Breast Neoplasms

NCT00072462 2024-09-19

IBIS-II DCIS

2,980 enrolled 14 charts

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT02918084 2024-05-08

GIM10-CONSENT

1,000 enrolled

Breast Neoplasms

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

766 enrolled

Breast Neoplasms

NCT00543127 2023-03-10

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

Phase 3 Terminated

870 enrolled 17 charts

Breast Neoplasms

NCT00301457 2023-02-21

DATA

1,914 enrolled

Breast Neoplasms

NCT00887380 2022-11-18

STARS

2,023 enrolled

Breast Neoplasms

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

434 enrolled

Advanced Breast Cancer

NCT00078832 2021-10-06

IBIS II

3,864 enrolled

Breast Neoplasms

NCT02730091 2021-02-01

VICTORIANE

Phase 3 Terminated

98 enrolled

Breast Neoplasms

NCT02511639 2020-12-03

MAIN-A

110 enrolled

Breast Cancer Metastatic

NCT02338310 2020-02-17

POETIC

4,486 enrolled

Breast Neoplasms

NCT00541086 2020-02-07

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

3,697 enrolled

Breast Neoplasms

NCT02097459 2016-05-25

Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer

600 enrolled

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT01402193 2014-06-25

Study of Arimidex and Radiotherapy Sequencing

220 enrolled

Breast Neoplasms, Camurati-Engelmann Syndrome

NCT00902954 2009-05-15

LEANEX

540 enrolled